Ads
related to: belimumab lupus nephritis fda approval- What About BENLYSTA?
Could BENLYSTA Be Another Option?
See the Data, Dosing & Resources.
- BENLYSTA Dosing Options
Consider Her Schedule And Needs.
Discover The Option That Fits Her.
- BENLYSTA Resource Center
Discover A Library Of Resources
Designed To Inform You. Learn More.
- BENLYSTA Video Library
See Video Stories From Peers &
Dig Into BENLYSTA Patient Profiles.
- But Why BENLYSTA?
See Clinical Trial Results & More
To Explore BENLYSTA For Yourself.
- BENLYSTA Safety Profile
What Your Patients May Experience.
Learn About Possible Side Effects.
- What About BENLYSTA?
Search results
Results From The WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.
Belimumab: GlaxoSmithKline: active lupus nephritis [1] Osimertinib: AstraZeneca: adjuvant therapy after tumor resection in non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R mutations Ansuvimab: Ridgeback Biotherapeutics: Ebola Zaire
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Ads
related to: belimumab lupus nephritis fda approval